1. Home
  2. PBH vs PHVS Comparison

PBH vs PHVS Comparison

Compare PBH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prestige Consumer Healthcare Inc.

PBH

Prestige Consumer Healthcare Inc.

HOLD

Current Price

$50.24

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$38.04

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBH
PHVS
Founded
1996
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.4B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
PBH
PHVS
Price
$50.24
$38.04
Analyst Decision
Buy
Buy
Analyst Count
3
11
Target Price
$75.33
$41.82
AVG Volume (30 Days)
406.7K
860.5K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.61
N/A
Revenue
$975,777,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.31
N/A
P/E Ratio
$81.62
N/A
Revenue Growth
36.77
N/A
52 Week Low
$42.62
$20.65
52 Week High
$71.07
$43.25

Technical Indicators

Market Signals
Indicator
PBH
PHVS
Relative Strength Index (RSI) 43.80 63.05
Support Level $49.73 $24.73
Resistance Level $51.57 N/A
Average True Range (ATR) 1.34 1.76
MACD -0.15 0.01
Stochastic Oscillator 6.11 47.88

Price Performance

Historical Comparison
PBH
PHVS

About PBH Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: